The SaVe Project-Sarcopenia and Vertigo in Aging Patients With Colorectal Cancer

Frequent adverse effects of chemotherapy in older adults are nausea and fatigue, but our research group have discovered a problem with many also suffering from sarcopenia, vertigo, dizziness, and peripheral neuropathy (CIPN) leading to balance and walking impairments causing increased risk of falls. Moreover, these symptoms are often underreported with inadequate awareness among health professionals leading to deficient focus on the need for targeted rehabilitation. A comprehensive geriatric assessment (CGA) can increase the number of frail, older patients completing chemotherapy and CGA-based interventions can decrease chemotherapy toxicity and improve health-related quality of life (HRQoL). Physical exercise has been shown to reduce muscle weakness, vertigo, dizziness, and impaired balance among older adults requiring limited resources. Therefore, this project aims to investigate the effectiveness of CGA and physical exercise to counteract muscle weakness, vertigo, instability, and impaired walking balance, during chemotherapy and to investigate the interaction between vertigo, postural stability and walking performance, and neuropathy and the prevalence of sarcopenia. The activities of specialized physical exercise planned in this intervention will, as hypothesized, result in a change in muscle strength, walking balance, self-perceived balance disabilities/dizziness, and fear of falling along with changes in peripheral nerve function and autonomic function and severity of CIPN which are the outcomes of this study. Accordingly, expectations are that this intervention will affect the HRQoL among older cancer patients with vertigo and walking impairments and reduce the number of falls and hospital admissions leading to a socioeconomic benefit.

• Falls [Срок оценки: Baseline, two, four, six, eight, ten, twelve, fourteen, sixteen, eighteen, twenty, twenty-two, and twenty-four weeks]
• Hospital contacts due to falls [Срок оценки: Baseline, three and six months]
• Balance disabilities/dizziness [Срок оценки: Baseline, three and six months]
• Fear of falling [Срок оценки: Baseline, three and six months]
• Health related quality of life [Срок оценки: Baseline, three and six months]
• Peripheral nerve function [Срок оценки: Baseline, three and six months]
• Autonomic function [Срок оценки: Baseline, three and six months]
• Chemotherapy induced peripheral neuropathy [Срок оценки: Baseline, three and six months]
• Muscle strength [Срок оценки: Baseline, three and six months]
• Body composition [Срок оценки: Baseline, three and six months]
• Muscle strength [Срок оценки: Baseline, three and six months]